Yüklüyor......
Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro
PT2385 is a first-in-class, selective small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α) developed for the treatment of advanced clear cell renal cell carcinoma. Preclinical results demonstrated that PT2385 has potent antitumor efficacy in mouse xenograft models of kidney cancer. It al...
Kaydedildi:
| Yayımlandı: | Drug Metab Dispos |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
The American Society for Pharmacology and Experimental Therapeutics
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5829541/ https://ncbi.nlm.nih.gov/pubmed/29363499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/dmd.117.079723 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|